



FW

PATENT

Case Docket No. ABGENIX.058A

Date: June 28, 2004


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Chen et al.
Appl. No. : 10/734,606
Filed : December 11, 2003
For : SYSTEM AND METHOD FOR
STABILIZING ANTIBODIES
WITH HISTIDINE
Examiner : Unknown
Group Art Unit : 1632

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

June 28, 2004

(Date)


Marc C. Baumgartner, Reg. No. 53,976


TRANSMITTAL LETTER


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement.
- (X) A PTO Form 1449 with Eight (8) references.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.


Marc C. Baumgartner
Registration No. 53,976
Attorney of Record
Customer No. 20,995
(619) 235-8550



INFORMATION DISCLOSURE STATEMENT

Applicant : Chen et al.
App. No. : 10/734,606
Filed : December 11, 2003
For : SYSTEM AND METHOD FOR STABILIZING
ANTIBODIES WITH HISTIDINE
Examiner : Unknown
Group Art Unit : 1632

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed is form PTO-1449 listing eight (8) references. Copies of U.S. patents and/or publications are not included herewith pursuant to PTO waiver of this requirement under 37 C.F.R. § 1.98(a)(2)(i) for applications filed after June 30, 2003. Copies of the other cited references, however, are enclosed.


This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,
KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 6/28/04

By: Marc C. Baumgartner

Marc C. Baumgartner
Registration No. 53,976
Attorney of Record
Customer No. 20,995
(619) 235-8550



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
ABGENIX.058AAPPLICATION NO.
10/734,606INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Chen et al.FILING DATE
December 11, 2003GROUP
1632

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	1	5,358,708	10/1994	Patel			
	2	5,580,856	12/1996	Prestrelski et al.			
	3	5,763,401	06/1998	Nayar			
	4	5,919,766	07/1999	Österberg et al.			
	5	6,150,584	11/2000	Kucherlapati et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

EXAMINER
INITIAL

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

	6	Huston et al., <u>Protein Engineering of Single-Chain Fv Analogs and Fusion Proteins</u> , <i>Methods in Enzymology</i> 203:46-63 (1991)
	7	Österberg et al., <u>Development of a Freeze-Dried Albumin-Free Formulation of Recombinant Factor VII SQ</u> , <i>Pharmaceutical Research</i> 14:892-898 (1997).
	8	Cleland et al., <u>A Specific Molar Ratio of Stabilizer to Protein is Required for Storage Stability of a Lyophilized Monoclonal Antibody</u> , <i>Journal of Pharmaceutical Sciences</i> 90(3)319-321 (2001)

S:\DOCS\MCB\MCB-2767.DOC
060804

EXAMINER

DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.